This segment focuses on the production and sale of life nutrition products, including a wide range of vitamins and related products. Zhejiang Medicine manufactures synthetic vitamin E, vitamin A, natural vitamin E, vitamin H, vitamin D3, coenzyme Q10, carotene, cantharidin, lutein, and lycopene. Research and development activities in this segment focus on improving the efficiency and purity of vitamin synthesis, exploring new applications of vitamins in health and wellness, and developing innovative formulations for enhanced bioavailability. The company utilizes advanced chemical synthesis and extraction technologies. The primary therapeutic areas addressed are general health and wellness, with a focus on providing essential nutrients for various life stages. The patient impact is improved health and well-being through nutritional supplementation. Zhejiang Medicine's market positioning is strong in China, with a competitive advantage in its established manufacturing capabilities and broad product portfolio. Future opportunities include expanding into international markets and developing new vitamin-based products. Regulatory aspects include compliance with food and drug administration standards and obtaining necessary certifications. There are no major partnerships or collaborations in this segment mentioned in the search results.

This segment encompasses the research, development, manufacturing, and commercialization of pharmaceutical products, including anti-drug resistant antibiotics, anti-malaria drugs, quinolones, and other pharmaceutical raw materials. Zhejiang Medicine is actively involved in the development of new drug formulations and the improvement of existing manufacturing processes. Research and development activities include the discovery of new drug candidates, optimization of synthesis routes, and clinical trials. The company utilizes advanced chemical synthesis, fermentation, and formulation technologies. The therapeutic areas covered include infectious diseases and other areas. The patient impact is the treatment and prevention of diseases through effective medications. Zhejiang Medicine's market positioning is strong in China, with a focus on providing essential medicines. Future opportunities include expanding the product portfolio, entering new therapeutic areas, and increasing international sales. Regulatory aspects include compliance with national and international drug regulations and obtaining necessary approvals for new drugs. The company has partnerships with Ambrx to develop and commercialize ARX788.